drugset
drugset / Trial / NCT05856331

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

NCT05856331 ↗

Phase 2 Completed 99 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema

Timeline

Start
2023-10-12
Primary completion
2025-08-06
Completion
2025-08-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alpha 1-Antitrypsin Protein / enzyme biologic 60 mg/kg Intravenous
Subject SAR447537 Protein / enzyme biologic — Intravenous

Indications

alpha 1-antitrypsin deficiency pulmonary emphysema